Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.29
-0.07 (-0.95%)
At close: May 8, 2026, 4:00 PM EDT
7.37
+0.08 (1.10%)
After-hours: May 8, 2026, 5:09 PM EDT
Kezar Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
53.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 7.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| Hyperion DeFi | 813.46K |
| ImageneBio | 800.00K |
| Entera Bio | 42.00K |
KZR News
- 5 weeks ago - Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies - TheFly
- 5 weeks ago - Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR - TheFly
- 5 weeks ago - Aurinia to acquire Kezar Life Sciences for $6.955 in cash per share plus CVR - TheFly
- 5 weeks ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 2 months ago - Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - Business Wire
- 4 months ago - Kezar Life Sciences: FDA grants Type C meeting to discuss zetomipzomib - TheFly
- 4 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 6 months ago - Kezar Life Sciences reports Q3 EPS ($1.53), consensus ($1.96) - TheFly